Ipsen (IPSEY) posted sales of 822.4 million euros for the first quarter of 2024, up 13.3% at CER, or 10.9% as reported, driven by the 16.2% increase in sales of the growth platforms and the increased contributions from new medicines, while Somatuline sales declined by 1.
Ipsen’s Onivyde is now FDA approved as a first-line treatment for metastatic pancreatic cancer, triggering a milestone payment to Merrimack Pharmaceuticals, the drug’s original developer. Merrimack plans to dissolve operations but its shareholders will receive payouts from the Ipsen payment.
Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam
Paris , 21 October 2021 - Ipsen , a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales. | June 16, 2023
Ipsen drug Bylvay is now FDA approved for treating pruritus, or severe itching, which is a complication of the rare liver disease Alagille syndrome. The oral drug was previously approved for treating pruritus in another rare inherited liver disease called PFIC.